Shaharyar Khan
Directeur Technique/Scientifique/R&D chez Rivus Pharmaceuticals, Inc.
Postes actifs de Shaharyar Khan
Sociétés | Poste | Début | Fin |
---|---|---|---|
Rivus Pharmaceuticals, Inc.
Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Directeur/Membre du Conseil | - | - |
Directeur Technique/Scientifique/R&D | - | - |
Historique de carrière de Shaharyar Khan
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Rivus Pharmaceuticals, Inc.
Rivus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rivus Pharmaceuticals, Inc. is a company dedicated to improving metabolic health by advancing a new class of medicines called controlled metabolic accelerators (CMAs). The company is based in Charlottesville, VA. Jayson Donald Alexander Dallas has been the CEO of the company since 2021. The company is a leader in mitochondrial biology and is developing a new class of medicines to address a primary driver of cardio-metabolic disease: obesity. Rivus' lead CMA is the investigational small molecule HU6 in development to treat obesity and associated metabolic diseases, including heart failure with preserved ejection fraction (HFpEF), metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes. | Health Technology |
- Bourse
- Insiders
- Shaharyar Khan
- Expérience